Michael V. Rocco

Effects of a CHANGE intervention to increase exercise maintenance following cardiac events

Shirley M. Moore, Jacqueline M. Charvat, Beverly L. Roberts, 2006, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study

R. Rosenson, E. Stroes, L. Cho, 2014, Cardiovascular Drugs and Therapy.

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

G. Watts, R. Rosenson, E. Bruckert, 2014, Journal of the American College of Cardiology.

New cholesterol guidelines: Worth the wait?

S. Hazen, L. Cho, Michael V. Rocco, 2014, Cleveland Clinic Journal of Medicine.

Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.

S. Hazen, D. Frid, L. Cho, 2013, American heart journal.

Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy

R. Rosenson, E. Stroes, L. Cho, 2014, Clinical cardiology.

Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience.

S. Hazen, D. Frid, L. Cho, 2013, American heart journal.

Cross-sectional study of quality of life and symptoms in chronic renal disease patients: the Modification of Diet in Renal Disease Study.

M. Rocco, R. Kaplan, J. Gassman, 1997, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy

R. Rosenson, E. Stroes, L. Cho, 2014, Clinical cardiology.